Evidence map›Paper›PMID 32392908›Full record

ReviewMolecules and cells2020

Ceramide and Sphingosine 1-Phosphate in Liver Diseases.

Woo-Jae Park, Jae-Hwi Song, Goon-Tae Kim, Tae-Sik Park

Open access · greenAbstract readReview
In one paragraph

Review in Molecules and cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. A Somatic Mutation in HIF-2α Affects Glucose and Lipid Metabolism via CD36 and Ceramide.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Woo-Jae ParkDepartment of Biochemistry, College of Medicine, Gachon University, Incheon 21999, Korea.ORCID https://orcid.org/0000-0002-5770-7096
Jae-Hwi SongDepartment of Life Science, Gachon University, Seongnam 13120, Korea.ORCID https://orcid.org/0000-0002-5000-1381
Goon-Tae KimDepartment of Life Science, Gachon University, Seongnam 13120, Korea.ORCID https://orcid.org/0000-0003-0621-0730
Tae-Sik ParkDepartment of Life Science, Gachon University, Seongnam 13120, Korea.ORCID https://orcid.org/0000-0002-4629-947X
Gachon University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The liver is an important organ in the regulation of glucose and lipid metabolism. It is responsible for systemic energy homeostasis. When energy need exceeds the storage capacity in the liver, fatty acids are shunted into nonoxidative sphingolipid biosynthesis, which increases the level of cellular ceramides. Accumulation of ceramides alters substrate utilization from glucose to lipids, activates triglyceride storage, and results in the development of both insulin resistance and hepatosteatosis, increasing the likelihood of major metabolic diseases. Another sphingolipid metabolite, sphingosine 1-phosphate (S1P) is a bioactive signaling molecule that acts via S1P-specific G protein coupled receptors. It regulates many cellular and physiological events. Since an increase in plasma S1P is associated with obesity, it seems reasonable that recent studies have provided evidence that S1P is linked to lipid pathophysiology, including hepatosteatosis and fibrosis. Herein, we review recent findings on ceramides and S1P in obesity-mediated liver diseases and the therapeutic potential of these sphingolipid metabolites.

Indexed as

AnimalsCeramidesHomeostasisHumansInsulin ResistanceLipid MetabolismLiverLiver DiseasesLysophospholipidsObesitySphingosineCeramidesLysophospholipidsSphingosinesphingosine 1-phosphateceramidefibrosisinsulin resistanceobesitysphingosine 1-phosphatesteatosis

Identifiers

PMID32392908
PMCPMC7264474
OpenAlexW3027955978

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.